A randomized, double-blind, placebo-controlled, dose-escalation Phase Ia clinical study to evaluate the safety, tolerability, and pharmacokinetics of MWN101 injection after single and multiple subcutaneous administration in healthy Chinese volunteers
Latest Information Update: 09 Sep 2025
At a glance
- Drugs MWN 101 (Primary)
- Indications Obesity; Type 2 diabetes mellitus
- Focus Adverse reactions
Most Recent Events
- 09 Sep 2025 New trial record